Incannex Healthcare Inc. (IXHL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $24.72M
Last updated: Nov 17, 2026 at 11:06 AM ET
Earnings
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 33.4% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 21.7, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Data
Related GNG Research
No research available
Be the first to write about IXHL
News
IXHL Valuation
- P/FCF
- -7.6x
- P/B
- 0.4x
IXHL Profitability: Margins, ROIC and FCF
Incannex Healthcare (IXHL) has an operating margin of 0.0% and a net margin of 0.0%. It posts -18.1% ROIC.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROIC
- -18.1%
- ROE
- -47.8%
- FCF yield
- -13.2%
Incannex Healthcare Competitors
The companies most similar to Incannex Healthcare (IXHL) include Scynexis, InMed Pharmaceuticals and Shuttle Pharmaceuticals.
Sector: Healthcare
Companies most similar to Incannex HealthcareIXHL Bull Case vs Bear Case
Bear case
- IXHL's quarterly revenue changed -100.0% year over year.
IXHL Earnings: Next Report
The next report from Incannex Healthcare (IXHL) is expected on Feb 11, 2027.
- Estimate revisions (30 days, fiscal period ending Dec 31, 2026)
- 1 up, 0 down
IXHL Earnings Date
IXHL reports Feb 11, 2027. The date is estimated.
Updated Nov 12, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About IXHL
When does IXHL report earnings?
Incannex Healthcare Inc. (IXHL) is expected to report earnings on Feb 11, 2027.
Does IXHL pay dividends?
Incannex Healthcare Inc. (IXHL) does not currently pay a regular dividend.
What is IXHL's market cap?
Incannex Healthcare Inc. (IXHL) has a market capitalization of $24.72M with a current stock price of $1.93.
IXHL pages: Overview, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.